Literature DB >> 1310036

Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in Swiss 3T3 cells.

M Saijo1, M Ui, T Enomoto.   

Abstract

We have investigated the amount of DNA topoisomerase II and phosphorylation of the enzyme in Swiss 3T3 cells during the transition from cell quiescence to proliferation. A relatively high level of phosphorylation was observed with proliferating cells while no or a very low level of phosphorylation was observed with quiescent cells. Phosphoamino acid analysis of the phosphorylated topoisomerase II revealed that the phosphorylated aminoacyl residue was serine. When quiescent cells were stimulated to grow by the addition of serum, DNA synthesis began to increase at 9 h after serum addition, reaching a maximum at 15 h and then declining. The amount of topoisomerase II began to increase at 6 h and reached a maximum at 22-27 h, corresponding to the G2 phase. The phosphorylation of topoisomerase II measured by pulse-labeling gradually increased from 6 to 18 h and reached a maximum at 22 h when the amount of the enzyme was maximum. The level of phosphorylation measured by continuous-labeling increased gradually up to 12 h and markedly up to 28 h, and then declined. The increase in the rate of phosphorylation in the G2 phase was affected by inhibiting DNA synthesis, but the increase in the amount of the enzyme was not. Thus, it was suggested that the regulation of phosphorylation of topoisomerase II differs from that of the amount of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310036     DOI: 10.1021/bi00117a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Type II topoisomerase activities in both the G1 and G2/M phases of the dinoflagellate cell cycle.

Authors:  Carmen K M Mak; Victor K L Hung; Joseph T Y Wong
Journal:  Chromosoma       Date:  2005-11-15       Impact factor: 4.316

2.  Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation.

Authors:  P S Shapiro; A M Whalen; N S Tolwinski; J Wilsbacher; S J Froelich-Ammon; M Garcia; N Osheroff; N G Ahn
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

3.  A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5' of an immunoglobulin promoter.

Authors:  C F Webb; K L Eneff; F H Drake
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

4.  Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.

Authors:  D A Burden; L J Goldsmith; D M Sullivan
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

5.  Topoisomerase II forms multimers in vitro: effects of metals, beta-glycerophosphate, and phosphorylation of its C-terminal domain.

Authors:  Y S Vassetzky; Q Dang; P Benedetti; S M Gasser
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

Review 6.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

7.  The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II.

Authors:  P R Caron; P Watt; J C Wang
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

8.  Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.

Authors:  A Haldane; K M Holdaway; G J Finlay; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Authors:  G J Finlay; E Marshall; J H Matthews; K D Paull; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 10.  Multilevel therapeutic targeting by topoisomerase inhibitors.

Authors:  P J Smith; S Souès
Journal:  Br J Cancer Suppl       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.